EUVIMEDEUVIMED entdecken
Kohortenstudie

Clinical outcomes of adjuvant nivolumab following neoadjuvant chemotherapy and esophagectomy in patients with esophageal cancer: A single-center retrospective cohort study

Naomichi Koga, Yasue Kimura, Rena Yokomizo, Munehide Terashi, Ayako Iwanaga, Yuta Kasagi, Masahiko Sugiyama, Keishi Sugimachi, Morita Masaru, Mototsugu Shimokawa, Eiji Oki

Surgery Today · 2026-06 · 56 (6) · 896-905

DOI: 10.1007/s00595-025-03187-8 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Surgery Today, online erschienen am 01.12.2025. Verfasst von Naomichi Koga und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Surgery, NHO Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka, 811-1395, Japan. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Esophagectomy, Nivolumab, Neoadjuvant Therapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: The CheckMate 577 trial revealed that adjuvant nivolumab administration following neoadjuvant chemoradiotherapy and surgery significantly improved the disease-free survival (DFS). However, evidence supporting its effectiveness following neoadjuvant chemotherapy and surgery for advanced esophageal cancer remains limited. This study evaluated the efficacy and safety of adjuvant nivolumab therapy in patients receiving neoadjuvant chemotherapy followed by esophagectomy. METHODS: We retrospectively analyzed 53 patients who underwent neoadjuvant chemotherapy followed by esophagectomy for advanced esophageal cancer between 2021 and 2024 years. Patients were divided into the adjuvant nivolumab and non-adjuvant groups. Clinicopathological factors, surgical outcomes, adverse events, and survival rates were compared between the groups. We also investigated the association between immune-related adverse events (irAEs) and survival outcome. RESULTS: Of the 53 patients, 15 (28%) received adjuvant nivolumab therapy. The DFS was significantly better in the adjuvant nivolumab group. In the multivariate analysis, although not significantly, adjuvant nivolumab was identified as a favorable prognostic factor. In total, 8 patients (53%) developed irAEs; those who developed irAEs and completed 1-year adjuvant nivolumab therapy showed a longer DFS than those without irAEs. CONCLUSION: Adjuvant nivolumab therapy following neoadjuvant chemotherapy and surgery may improve the DFS in patients with advanced esophageal cancer. Appropriate irAE management may support therapy completion and improve patient outcome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal NeoplasmsEsophagectomyNivolumabNeoadjuvant TherapyAntineoplastic Agents, ImmunologicalHumansRetrospective StudiesMaleFemaleMiddle AgedChemotherapy, AdjuvantAgedTreatment OutcomeSurvival RateCohort StudiesDisease-Free SurvivalAdultCombined Modality Therapy

Stichwörter der Autor:innen

Adjuvant therapyEsophageal cancerImmune checkpoint inhibitorsNivolumab

Substanzen

NivolumabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Gastroenterological Surgery, NHO Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka, 811-1395, Japan.
  • Department of Gastroenterological Surgery, NHO Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka, 811-1395, Japan. kimura.yasue.740@m.kyushu-u.ac.jp.
  • Department of Advanced Medicine and Innovative Technology, Kyushu University Hospital, 3-1-1, Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. kimura.yasue.740@m.kyushu-u.ac.jp.
  • Department of Hepatobiliary-Pancreatic Surgery, NHO Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka, 811-1395, Japan.
  • Department of Biostatistics, Yamaguchi University Graduate School of Medicine, 1-1-1 Minamikogushi, Ube, 755-8505, Yamaguchi, Japan.
  • Department of Advanced Medicine and Innovative Technology, Kyushu University Hospital, 3-1-1, Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.

Zitieren

APA

Koga, N., Kimura, Y., Yokomizo, R., Terashi, M., Iwanaga, A., Kasagi, Y., Sugiyama, M., Sugimachi, K., Masaru, M., Shimokawa, M., & Oki, E. (2026). Clinical outcomes of adjuvant nivolumab following neoadjuvant chemotherapy and esophagectomy in patients with esophageal cancer: A single-center retrospective cohort study. Surgery Today, 56(6), 896-905. https://doi.org/10.1007/s00595-025-03187-8

Vancouver

Koga N, Kimura Y, Yokomizo R, Terashi M, Iwanaga A, Kasagi Y, et al. Clinical outcomes of adjuvant nivolumab following neoadjuvant chemotherapy and esophagectomy in patients with esophageal cancer: A single-center retrospective cohort study. Surgery Today. 2026;56(6):896-905. doi:10.1007/s00595-025-03187-8

BibTeX
@article{Koga2026,
  author = {Koga, Naomichi and Kimura, Yasue and Yokomizo, Rena and Terashi, Munehide and Iwanaga, Ayako and Kasagi, Yuta and Sugiyama, Masahiko and Sugimachi, Keishi and Masaru, Morita and Shimokawa, Mototsugu and Oki, Eiji},
  title = {Clinical outcomes of adjuvant nivolumab following neoadjuvant chemotherapy and esophagectomy in patients with esophageal cancer: A single-center retrospective cohort study},
  journal = {Surgery Today},
  year = {2026},
  volume = {56},
  number = {6},
  pages = {896--905},
  doi = {10.1007/s00595-025-03187-8}
}
Kostenlos starten →